Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Consumer Healthcare Inc.

https://www.prestigebrands.com/

Latest From Prestige Consumer Healthcare Inc.

US Q4 Consumer Health Earnings Preview: Will Demand Or Shortage Have More Impact?

Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.

Sales & Earnings Dietary Supplements

Prestige Consumer Targets Improving Delivering On Demand, Considers Price Hikes As Costs Grow

Around half its reported 4.7% growth to $289.3 million in latest came from price increases. Impact on supply chain continues from problems caused by novel coronavirus pandemic.

Consumer Sales & Earnings

US Q3 Consumer Health Earnings Preview: Coming Changes Overshadow Current Conditions?

Rather than reflecting what’s coming in the way of spinoffs, leadership, product approvals or deal closings, firms’ July-September results will reveal influences from inflation and supply chain problems. Like manufacturers across industries, US consumer health product firms are dealing with US currency strengthening and potentially driving down revenues through losses in foreign exchange.

Sales & Earnings OTC Drugs

Prestige Consumer Opens Its FY2023 With Revenue Thirst Quenched By Hydralyte International Sales

Hydralyte line has 90% share in Australia’s hydration market and accounted for a large share of firm’s overall sales growth in its latest quarter as 28.9% international sales growth to $34.5m offset flat North American results at $242.4m.

Sales & Earnings Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Prestige Brands, Inc.
UsernamePublicRestriction

Register